Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine.
Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine.
复制标题
临床甲硝唑耐药的阴道毛滴虫对硝唑尼特、丰加霉素和 2-氟-2-脱氧腺苷的体外敏感性。
DOI：
10.1007/s00436-010-1938-3
复制
发表时间：
2010
影响因子：
2
通讯作者：
Upcroft,JacquelineA
中科院分区：
文献类型：
--
作者：
Wright,JanelleM;Dunn,LindaA;Kazimierczuk,Zygmunt;Burgess,AnitaG;Krauer,KeniaG;Upcroft,Peter;Upcroft,JacquelineA
This study investigates the susceptibility of a clinically metronidazole (Mz)-resistant isolate ofTrichomonas vaginalisto alternative anti-trichomonal compounds. The microaerobic minimal inhibitory concentration (MIC) of the 5-nitroimidazole (NI) drug, Mz, against a typical Mz-susceptible isolate ofT. vaginalisis around 3.2 µM Mz while the clinically, highly Mz-resistant isolate has an MIC of 50–100 µM. This isolate was cross-resistant to other members of the 5-NI family of compounds including tinidazole and other experimental compounds and maintained resistance under anaerobic conditions. In addition, this isolate was cross-resistant to the 5-nitrothiazole compound nitazoxanide and the 5-nitrofuran derivative, furazolidone. Adenosine analogues toyocamycin and 2-fluoro-2′-deoxyadenosine with no nitro group were also less effective against the clinically Mz-resistant isolate than a Mz-susceptible one. Three other isolates which were determined to be Mz-resistant soon after isolation lost resistance in the long term. One other isolate has maintained some level of permanent Mz resistance (MIC of 25 µM). A multi-drug resistance mechanism may be involved in these clinically Mz-resistant isolates.
